Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
U. Keilholz(Franklin University), Maria Pritsch(Heidelberg University), A. Benhammouda, Alexander M.M. Eggermont(University Medical Center Utrecht), Christian Conradt, Thierry Dorval(Centre Hospitalier Universitaire Brugmann), Sewa S. Legha(The University of Texas MD Anderson Cancer Center), Reinhard Dummer(University Hospital of Zurich), Carmen Scheibenbogen(University of Freiburg), E.‐B. Bröcker, D. Khayat, N. Thatcher(Humboldt-Universität zu Berlin), Barry W. Hancock(Weston Park Cancer Centre), S.H. Goey, M. F. Avril, Martin Gore(Imperial College London), Cornelis J.A. Punt(Utrecht University)
Cited by 199
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k